Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TRIM33

Gene summary for TRIM33

Gene summary.

Gene information	Species	Human
	Gene symbol	TRIM33
	Gene ID	51592
	Gene name	tripartite motif containing 33
	Gene Alias	ECTO
	Cytomap	1p13.2
	Gene Type	protein-coding
	GO ID	GO:0000122
	UniProtAcc	B3KN30

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
51592	TRIM33	HTA11_3410_2000001011	Human	Colorectum	AD	2.76e-09	-4.08e-01	0.0155
51592	TRIM33	HTA11_866_3004761011	Human	Colorectum	AD	1.57e-02	-3.47e-01	0.096
51592	TRIM33	HTA11_7696_3000711011	Human	Colorectum	AD	1.90e-05	-2.68e-01	0.0674
51592	TRIM33	HTA11_99999974143_84620	Human	Colorectum	MSS	2.87e-05	-2.99e-01	0.3005
51592	TRIM33	A001-C-207	Human	Colorectum	FAP	1.95e-05	-2.68e-01	0.1278
51592	TRIM33	A015-C-203	Human	Colorectum	FAP	4.38e-30	-3.16e-01	-0.1294
51592	TRIM33	A015-C-204	Human	Colorectum	FAP	6.80e-12	-3.84e-01	-0.0228
51592	TRIM33	A014-C-040	Human	Colorectum	FAP	2.62e-07	-4.83e-01	-0.1184
51592	TRIM33	A002-C-201	Human	Colorectum	FAP	2.25e-17	-3.29e-01	0.0324
51592	TRIM33	A002-C-203	Human	Colorectum	FAP	2.07e-06	-2.61e-01	0.2786
51592	TRIM33	A001-C-119	Human	Colorectum	FAP	1.23e-12	-5.37e-01	-0.1557
51592	TRIM33	A001-C-108	Human	Colorectum	FAP	1.01e-18	-2.56e-01	-0.0272
51592	TRIM33	A002-C-205	Human	Colorectum	FAP	1.16e-24	-3.32e-01	-0.1236
51592	TRIM33	A001-C-104	Human	Colorectum	FAP	1.42e-06	-2.88e-01	0.0184
51592	TRIM33	A015-C-005	Human	Colorectum	FAP	4.05e-05	-2.23e-01	-0.0336
51592	TRIM33	A015-C-006	Human	Colorectum	FAP	4.37e-16	-3.54e-01	-0.0994
51592	TRIM33	A015-C-106	Human	Colorectum	FAP	2.03e-15	-1.88e-01	-0.0511
51592	TRIM33	A002-C-114	Human	Colorectum	FAP	3.15e-21	-3.97e-01	-0.1561
51592	TRIM33	A015-C-104	Human	Colorectum	FAP	1.17e-32	-4.17e-01	-0.1899
51592	TRIM33	A001-C-014	Human	Colorectum	FAP	1.59e-14	-3.21e-01	0.0135

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00902873	Skin	AK	regulation of cellular response to growth factor stimulus	53/1910	304/18723	7.10e-05	1.02e-03	53
GO:000717817	Skin	AK	transmembrane receptor protein serine/threonine kinase signaling pathway	57/1910	355/18723	3.69e-04	3.61e-03	57
GO:000717910	Skin	AK	transforming growth factor beta receptor signaling pathway	35/1910	198/18723	8.69e-04	7.17e-03	35
GO:00717725	Skin	AK	response to BMP	30/1910	165/18723	1.24e-03	9.40e-03	30
GO:00717735	Skin	AK	cellular response to BMP stimulus	30/1910	165/18723	1.24e-03	9.40e-03	30
GO:00305102	Skin	AK	regulation of BMP signaling pathway	20/1910	96/18723	1.46e-03	1.06e-02	20
GO:00305094	Skin	AK	BMP signaling pathway	27/1910	152/18723	2.97e-03	1.87e-02	27
GO:00170157	Skin	AK	regulation of transforming growth factor beta receptor signaling pathway	23/1910	128/18723	5.03e-03	2.83e-02	23
GO:19038448	Skin	AK	regulation of cellular response to transforming growth factor beta stimulus	23/1910	131/18723	6.70e-03	3.54e-02	23
GO:007155917	Skin	cSCC	response to transforming growth factor beta	95/4864	256/18723	5.21e-05	5.31e-04	95
GO:007156025	Skin	cSCC	cellular response to transforming growth factor beta stimulus	92/4864	250/18723	9.65e-05	8.99e-04	92
GO:000717917	Skin	cSCC	transforming growth factor beta receptor signaling pathway	69/4864	198/18723	3.39e-03	1.84e-02	69
GO:007155919	Thyroid	PTC	response to transforming growth factor beta	131/5968	256/18723	9.20e-11	3.17e-09	131
GO:007156019	Thyroid	PTC	cellular response to transforming growth factor beta stimulus	126/5968	250/18723	7.34e-10	2.19e-08	126
GO:000717919	Thyroid	PTC	transforming growth factor beta receptor signaling pathway	104/5968	198/18723	1.20e-09	3.47e-08	104
GO:001701515	Thyroid	PTC	regulation of transforming growth factor beta receptor signaling pathway	69/5968	128/18723	1.92e-07	3.51e-06	69
GO:190384415	Thyroid	PTC	regulation of cellular response to transforming growth factor beta stimulus	70/5968	131/18723	2.47e-07	4.31e-06	70
GO:000717819	Thyroid	PTC	transmembrane receptor protein serine/threonine kinase signaling pathway	156/5968	355/18723	1.02e-06	1.51e-05	156
GO:00900925	Thyroid	PTC	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	108/5968	256/18723	3.07e-04	2.14e-03	108
GO:009028712	Thyroid	PTC	regulation of cellular response to growth factor stimulus	120/5968	304/18723	2.87e-03	1.42e-02	120

Page: 1 2 3 4 5 6 7

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TRIM33

SNV

Missense_Mutation

novel

c.2950N>A

p.Glu984Lys

p.E984K

Q9UPN9

protein_coding

tolerated(0.19)

benign(0.049)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

TRIM33

SNV

Missense_Mutation

novel

c.2134N>A

p.Gln712Lys

p.Q712K

Q9UPN9

protein_coding

tolerated(1)

benign(0.191)

TCGA-AN-A03Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TRIM33

SNV

Missense_Mutation

c.2923N>C

p.Cys975Arg

p.C975R

Q9UPN9

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AR-A255-01

Breast

breast invasive carcinoma

Female

<65

I/II

Targeted Molecular therapy

trastuzumab

TRIM33

SNV

Missense_Mutation

novel

c.3162N>G

p.Ile1054Met

p.I1054M

Q9UPN9

protein_coding

tolerated(0.05)

possibly_damaging(0.674)

TCGA-BH-A0DI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

TRIM33

insertion

Nonsense_Mutation

novel

c.1321_1322insCAGAAAGAGCTTTTTAAAATA

p.His441delinsProGluArgAlaPheTerAsnAsn

p.H441delinsPERAF*NN

Q9UPN9

protein_coding

TCGA-A8-A0A4-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

TRIM33

SNV

Missense_Mutation

novel

c.3079N>A

p.Asp1027Asn

p.D1027N

Q9UPN9

protein_coding

deleterious(0.02)

probably_damaging(0.998)

TCGA-C5-A7X5-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

carboplatin

TRIM33

SNV

Missense_Mutation

c.3363G>C

p.Glu1121Asp

p.E1121D

Q9UPN9

protein_coding

tolerated(0.31)

benign(0.007)

TCGA-EK-A2PG-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

TRIM33

SNV

Missense_Mutation

novel

c.3301N>A

p.Val1101Ile

p.V1101I

Q9UPN9

protein_coding

tolerated(0.45)

benign(0)

TCGA-5M-AAT6-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Unknown

TRIM33

SNV

Missense_Mutation

c.1154A>T

p.Glu385Val

p.E385V

Q9UPN9

protein_coding

deleterious(0)

possibly_damaging(0.874)

TCGA-A6-2686-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

TRIM33

SNV

Missense_Mutation

novel

c.2045N>C

p.Asp682Ala

p.D682A

Q9UPN9

protein_coding

deleterious(0)

possibly_damaging(0.837)

TCGA-A6-6141-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Chemotherapy

5-fu

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1